{"id":"W2552542954","doi":"10.1182/blood.v116.21.1962.1962","title":"Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Pharmacokinetics; Adverse effect; Phases of clinical research; Refractory (planetary science); Cohort; Toxicity; Chemotherapy; Cancer; Tolerability; Nausea; Gastroenterology; Surgery; Oncology; Pharmacology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001744374,0.001192771,0.001859241,0.0005187549,0.0003271845,0.000790498,0.0007277722,0.0007559752,0.002287894],"category_scores_gemma":[0.001038533,0.0004549042,0.001353398,0.0004166174,0.0006518715,0.0006644153,0.0002781694,0.002526961,0.0006150411],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001045464,"about_ca_system_score_gemma":0.0009019816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006064239,"about_ca_topic_score_gemma":0.001427417,"domain_scores_codex":[0.999395,0.0002958137,0.00003695762,0.0001049251,0.00007479256,0.00009245121],"domain_scores_gemma":[0.9989318,0.0002513187,0.0002479889,0.000107069,0.00007997377,0.0003817446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.586147,0.06825113,0.02069614,0.0009584719,0.002383976,0.0004138848,0.0005700128,0.004901377,0.1918553,0.0002743959,0.003368237,0.1201801],"study_design_scores_gemma":[0.1542104,0.7650579,0.05114361,0.00004249194,0.001467159,0.0007152859,0.00007169786,0.001949938,0.0215821,0.0001543506,0.003556601,0.00004852449],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939668,0.001556452,0.0006338066,0.0001342873,0.00003194371,0.001150366,0.0009936107,0.00006758486,0.001464965],"genre_scores_gemma":[0.9946074,0.0007161834,0.0009014328,0.0001981602,0.00005943354,0.0005865576,0.001926686,0.0000226565,0.0009814479],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002287894,"threshold_uncertainty_score":0.009225249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01073555258037245,"score_gpt":0.2971416175396531,"score_spread":0.2864060649592806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}